메뉴 건너뛰기




Volumn 113, Issue 8, 2005, Pages 414-417

Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention

Author keywords

Fibrate; HDL cholesterol; Metabolic syndrome; Niacin; Nicotinic acid

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

EID: 25444431757     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865940     Document Type: Short Survey
Times cited : (12)

References (21)
  • 1
    • 33144461460 scopus 로고    scopus 로고
    • Clinical practice recommendations 2005
    • American Diabetes Association. Clinical practice recommendations 2005. Diab Care 2005; 28 (Suppl 1): 4-37
    • (2005) Diab Care , vol.28 , Issue.SUPPL. 1 , pp. 4-37
  • 2
    • 20544454535 scopus 로고    scopus 로고
    • Torcetrapib and atorvastatin - Should marketing drive the research agenda?
    • Avorn J. Torcetrapib and atorvastatin - should marketing drive the research agenda? N Engl J Med 2005; 352: 2573-2576
    • (2005) N Engl J Med , vol.352 , pp. 2573-2576
    • Avorn, J.1
  • 4
    • 0034604225 scopus 로고    scopus 로고
    • Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
    • BIP Study Investigation. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27
    • (2000) Circulation , vol.102 , pp. 21-27
  • 5
    • 11844296800 scopus 로고    scopus 로고
    • Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
    • Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. J Am Coll Cardiol 2005; 45: 185-197
    • (2005) J Am Coll Cardiol , vol.45 , pp. 185-197
    • Birjmohun, R.S.1    Hutten, B.A.2    Kastelein, J.J.3    Stroes, E.S.4
  • 6
    • 0023910325 scopus 로고
    • Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid
    • Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-418
    • (1988) Acta Med Scand , vol.223 , pp. 405-418
    • Carlson, L.A.1    Rosenhamer, G.2
  • 7
    • 0016630250 scopus 로고
    • Clofibrate and niacin in coronary heart disease
    • Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381
    • (1975) JAMA , vol.231 , pp. 360-381
  • 8
    • 25444461793 scopus 로고    scopus 로고
    • Praxisleitlinien
    • Deutsche Diabetes Gesellschaft. Praxisleitlinien. Diab Stoffw 2002; 11 (Suppl 2): 3-5
    • (2002) Diab Stoffw , vol.11 , Issue.SUPPL. 2 , pp. 3-5
    • Gesellschaft, D.D.1
  • 10
    • 12444318777 scopus 로고    scopus 로고
    • The need for a large-scale trial of fenofibrate therapy in diabetes: The rationale and design of the fenofibrate intervention and event lowering in Diabetes (FIELD) study
    • The Field Study Investigators. The need for a large-scale trial of fenofibrate therapy in diabetes: the rationale and design of the fenofibrate intervention and event lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 2004: 1-11
    • (2004) Cardiovasc Diabetol , pp. 1-11
  • 11
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3    Heinonen, O.P.4    Heinsalmi, P.5    Helo, P.6    Huttunen, J.K.7    Kaitaniemi, P.8    Koskinen, P.9    Manninen, V.10
  • 12
    • 0342506477 scopus 로고    scopus 로고
    • Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
    • Lopid Coronary Angiography Trial (LOCAT) Study Group
    • Frick MH, Syyanne M, Nieminen MS, Kauma H, Majajalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96: 2137-2143
    • (1997) Circulation , vol.96 , pp. 2137-2143
    • Frick, M.H.1    Syyanne, M.2    Nieminen, M.S.3    Kauma, H.4    Majajalme, S.5    Virtanen, V.6    Kesaniemi, Y.A.7    Pasternack, A.8    Taskinen, M.R.9
  • 13
    • 0018412417 scopus 로고
    • Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study
    • Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979; 90: 85-91
    • (1979) Ann Intern Med , vol.90 , pp. 85-91
    • Kannel, W.B.1    Castelli, W.P.2    Gordon, T.3
  • 14
    • 21544467275 scopus 로고    scopus 로고
    • Pathophysiology of coronary artery disease
    • Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488
    • (2005) Circulation , vol.111 , pp. 3481-3488
    • Libby, P.1    Theroux, P.2
  • 15
    • 14944381287 scopus 로고    scopus 로고
    • HDL as a target in the treatment of atherosclerotic cardiovascular disease
    • Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature 2005; 4: 193-205
    • (2005) Nature , vol.4 , pp. 193-205
    • Linsel-Nitschke, P.1    Tall, A.R.2
  • 16
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
    • Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418
    • (1999) N Engl J Med , vol.341 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3    Fye, C.L.4    Anderson, J.W.5    Elam, M.B.6    Faas, F.H.7    Linares, E.8    Schaefer, E.J.9    Schectman, G.10    Wilt, T.J.11    Wittes, J.12
  • 17
    • 0037643549 scopus 로고    scopus 로고
    • Fighting against the "hypertriglyceridaemic waist": A new international institute for the metabolic syndrome
    • Schatz H, Wehling M. Fighting against the "hypertriglyceridaemic waist": a new international institute for the metabolic syndrome. Exp Clin Endocrinol Diabetes 2003; 111: 119-120
    • (2003) Exp Clin Endocrinol Diabetes , vol.111 , pp. 119-120
    • Schatz, H.1    Wehling, M.2
  • 18
    • 18844401094 scopus 로고    scopus 로고
    • Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: A position paper developed by a European Consensus Panel
    • Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21: 665-682
    • (2005) Curr Med Res Opin , vol.21 , pp. 665-682
    • Shepherd, J.1    Betteridge, J.2    Van Gaal, L.3
  • 19
    • 0037898380 scopus 로고    scopus 로고
    • Diabetic dyslipidemia: From basic research to clinical practise
    • Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practise. Diabetologia 2003; 46: 733-749
    • (2003) Diabetologia , vol.46 , pp. 733-749
    • Taskinen, M.R.1
  • 20
    • 10044281651 scopus 로고    scopus 로고
    • Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3509-3511
    • (2004) Circulation , vol.110 , pp. 3509-3511
    • Taylor, A.J.1    Sullenberger, L.E.2    Lee, H.J.3    Lee, J.K.4    Grace, K.A.5
  • 21
    • 0346872978 scopus 로고    scopus 로고
    • Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials
    • Vrecer M, Turk S, Drinover J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003; 12: 567-577
    • (2003) Int J Clin Pharmacol Ther , vol.12 , pp. 567-577
    • Vrecer, M.1    Turk, S.2    Drinover, J.3    Mrhar, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.